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ABSTRACT
Nguyen, Duong Thuy. MS. The University of Memphis. August/2010. Design and
Evaluation of Chitosan-Calcium Phosphate Scaffolds Constructed from Air Dried and
Lyophilized Microspheres. Major professor: Joel D. Bumgardner

The orthopedic clinical demand for bone grafts is a persistent problem for patients with
age-related bone fractures and diseased bone defects. The aim of this study was to use
calcium phosphate, a biomimetic ceramic with high compressive strength, and chitosan, a
natural biodegradable and biocompatible polymer, to construct microsphere-based
composite scaffolds to serve as a bone graft. Two types of scaffolds,(1) air-dried
microspheres (AD) and (2) solid air-dried and lyophilized microsphere combination
(FDAD), were evaluated in vitro for mineralization and enzymatic degradation. The
combination FDAD scaffold showed on average ~80% increase (p<0.01) in cell number
per scaffold mass compared to AD because of the larger surface area advantage. Due to
the higher cell number, the production of collagen was ~31% greater (p<0.01) on FDAD
scaffolds compared to AD scaffolds. However, scanning electron micrographs indicated
minimal matrix deposition for both scaffold types. The AD scaffolds had a three-fold
compressive strength advantage compared to FDAD scaffolds. These results indicate
FDAD scaffolds have more osteogenic potential based on cell growth and collagen
elaboration, but AD scaffolds demonstrated higher compressive strength.
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PREFACE

This thesis presents research work on the construction and organization of composite
chitosan calcium phosphate microsphere based scaffolds for use in bone tissue
engineering. It is planned to have the results of this thesis work submitted as a manuscript
to Journal of Biomedical Materials Research A.
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CHAPTER 1: LITERATURE REVIEW
Bone Biology
Bone is a complex and dynamic tissue in its physiological properties and threedimensional (3D) organization. Bone responds to many physical, biological, and
endocrine stimuli.1 It is continually undergoing renewal depending on internal and
external mediators. Bone tissue is considered a connective tissue with a complex
organization consisting of bone cells embedded in bone extracellular matrix and bone
marrow with its blood capillary network.2, 3
There are 206 bones in the adult body each providing structural support and rigid
mechanical stability while allowing for flexibility with its variation in sizes, shapes, and
joints.2 In general, bone matrix is a composite of an organic matrix (collagen fibers and
proteoglycans) and a mineral phase (hydroxyapatite-like) in which the ductile fibers
reinforce the brittle hydroxyapatite minerals. This composite organization of bone
provides high mechanical strength for protection against impact and trauma.1-4
The architecture of bone can be classified into two types – cancellous and cortical
– because of its density, porosity, and pore size. Cortical bone is the highly compact bone
with 10% porosity and small pores while cancellous bone is 75-95% porous with pore
sizes of 200-900µm.2 These differences dictate the mechanical strength and functionality
each serve within the bone.2, 3, 5
The highly dense cortical bone is found at the outer lining of most bones
including long bone as the first line of defense against impact since it is stronger and
heavier than cancellous bone. Its compressive modulus is about 17.0 GPa in the
longitudinal direction, ~11.5 GPa in the transverse direction, and ~3.3GPa in shear.2

1

Cortical bone has a cylindrical organization of parallel collagen fiber layers called
circumferential lamellae. Depending on the bone, there is a spatial difference between the
outer and inner circumferential lamellae. These cylindrical lamellae are aligned
longitudinal to the bone providing high compressive strength to transmit load. However,
it is prone to fracture during perpendicular impact.2
Cancellous bone also known as trabecular or spongy bone is the interior network
of struts or trabeculae in a 3D organization forming interconnections. Trabecular bone
has the same lamellae organization but it is lighter and less stiff than cortical bone
because of its porosity and orientation of the lamellae. The trabeculae are about 200µm in
thickness for healthy bone with varying density but can reduce significantly with
osteoporotic bone. The longitudinal compressive modulus for cancellous bone with long
bones can vary according to location – 445MPa at the proximal tibia, 389MPa for the
femur, and 291MPa for the lumbar spine.2
This dynamic tissue is continuously undergoing renewal regulated by osteogenic
cells differentiated from mesenchymal stem cells (MSC), cytokines, and growth factors.
Osteoblasts, osteoclasts, and osteocytes are the specialized bone cells responsible bone
production, remodeling, and repair. During bone resorption and remodeling, osteoclasts
are recruited to break down old bone while osteoblasts are recruited to synthesize new
bone. When bone formation occurs, some osteoblasts are embedded within the matrix and
differentiate into osteocytes. Osteocytes maintain bone viability and functionality by
communicating with each other through small canals and with the rest of the body
through the blood capillary system of bone marrow networking throughout bone.6 The
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resorption process creates pits on the bone surface for the osteoblasts to settle to
regenerate new bone at the eroded surface.6
When bone is injured, it has the inherent physiological response mechanisms to
heal, repair, and remodel itself to its pre-injured condition. Bone fractures can vary in
complexity and patterns. For small and simple fractures, the healing process can be
initiated when the fracture site is stabilized allowing for biochemical and biomechanical
stimulation of bone cells.6-8 The process starts with non-specific signaling to respond to
the trauma causing inflammation and haematoma formation, proceeding to fracture
bridging via soft callus, then hard callus formation, and finally specific regulation of bone
remodeling.6-12 Osteoclasts differentiated from MSCs remodel the woven hard callus into
cortical and trabecular bone in the appropriate configuration.6 However, for more
complex fractures and defects with critical size gaps (e.g. 8 mm in humans) that disrupt
bone-to-bone interaction, normal physiological healing is inhibited, which will result in
bone nonunion.13 Therefore, surgical intervention such as bone graft implantation in
conjunction with internal fixation is required to restore the bone continuity and stability
to induce bone union.

Bone grafts
In the United States alone, over 500,000 bone grafting procedures have been
performed and demand will increase with age-related fractures as the ≥65 age group is
projected to reach 51.5 million in 2020.14, 15 Implantation of bone grafts with internal
fixation devices in long bone fractures promotes bone healing and formation to restore
bone continuity at the fracture gap. The grafts serve as a temporary support with some
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mechanical integrity and a favorable environment for osteogenesis, osteoconduction, and
possible osteoinduction. Osteogenesis is the process of bone formation and regeneration.6
Osteoconduction is the facilitation of bone cell migration, differentiation, and
mineralization while osteoinduction is an active facilitation of bone cell recruitment and
formation by growth factors and cytokines embedded in the graft.6 Commonly used bone
grafts are autografts and allografts which are extracted bone tissue that maintain some
bone physiochemical properties.16, 17 However, there are limitations associated their use
including prolonged surgical time and loss of bone bioactive properties.4, 18

Autografts
The gold standard for treating large bone defects are autografts.18 Autografts are
autologous bone commonly extracted from the iliac crest of the patient. The autograft
retains its osteoinductive and osteoconductive properties but only some osteogenicity due
to cell death during the transplanation.18, 19 However, the harvesting induces additional
pain, blood loss, and surgical time to the patient, which can lead to tissue morbidity,
healing delay, and other complications. For patients with old age or degenerative bone
diseases, poor bone quality and other health risks, the use of autografts is limited. Also
the quantity available for extraction is a limitation especially for patients with multiple
fracture sites.5

Allografts
An alternative to autografts is allograft, which is donor bone tissue. The use of
allografts accounts for more than one third of bone grafts used in the United States.5
Allografts are mostly used in a frozen irradiated or freeze-dried irradiated form. The
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donor tissue undergoes controlled and regulated processes to remove the cellular phase
and eliminate the possibility of immunological rejection along with viral transmission,
respectively. However, these processes deteriorate the physiochemical and biomechanical
properties of the donor bone by eliminating viable cells.1, 5, 20 For cancellous bone, there
is no structural strength, no osteogenicity, and little osteoinductivity left after the harsh
processing.21 For the cortical donor bone, there is no retention of osteoinductivity and
osteogenicity.21 Furthermore, the variability in bone quality of the donor tissue is a major
cause of variability in clinical results since responses are patient specific.5
Consequently, bone tissue engineering focuses the design and fabrication of
synthetic constructs to serve as a bone graft substitute to overcome limitations of current
auto- and allo-graft materials. Currently, there are commercially available synthetic bone
scaffolds and substitutes for clinical applications including craniofacial defects, spinal
fusion, and segmental bone loss.22
Bone tissue engineering
In bone tissue engineering, researchers are investigating the potential to fabricate
bone substitutes or scaffolds that can simulate physiological functions of bone for healing
fractures and defects. The design criteria for constructing a scaffold are mimicry of
bone’s physical and biological properties. From the engineering perspective, an ideal
scaffold is biocompatible, porous in structure for tissue infiltration and vascularization,
osteoconductive, osteoinductive, biodegradable, and biomechanically strong to promote
bone healing and regeneration.3, 16, 23 Furthermore, clinical needs require the scaffolds to
have ease of handling, immediate functionality, retention of shape, and radiographically
distinguishable.24
5

a. Architecture
The shape and three-dimensional (3D) organization of the scaffold can affect the
attachment, growth, and proliferation of bone cells, the exchange of nutrients and waste,
and blood capillary formation.3, 16 Depending on the site of fracture, the 3D structure of
the scaffold can vary from highly dense cortical bone to highly porous cancellous bone or
a combination of both. For segmental bone repair like the femur, a combination of
cortical and cancellous arrangement is necessary to mimic the functionality of the loss
bone. Even though cortical bone is highly dense, it still has porosity. Porosity is an
attribute of bone since bone is highly vascular to provide nutrition and communication
exchange. Designs with interconnected pores >200µm have a continuous pathway that is
more favorable for angiogenesis and cellular exchange of signaling and waste/nutrients.3,
23

However, high porosity can reduce the scaffold’s mechanical strength so designs

optimize between porosity and mechanical integrity.
In addition to overall architecture, surface micro-topography is also an important
aspect for implant integration since surface roughness enhances attachment of cells and
bone matrix.1 Surface roughness can enhance osteoclast attachment and surface grooves
guide osteoblast movements.25, 26

b. Biocompatibility
The scaffolds should elicit no immune responses from the host that causes
inflammation or rejection but instead promote responses to enhance bone healing and
formation.16 The ideal scaffold environment promotes bone cell attachment, proliferation,
and differentiation.1 As the scaffold is resorbed, the by-products should be nontoxic and
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easily excreted. Different synthetic and natural materials elicit by-products that are
handled by the body in various ways.

c. Osteoinductivity
By functionalizing the scaffolds with growth factors and cytokines, the scaffold
can induce mesenchymal stem cells to differentiate into osteoblasts to form new bone.24
Inductive growth factors such as bone morphogenic proteins, vascular endothelial growth
factors, and platelet-derived growth factors are currently used to up regulate bone cell
morphogenesis and osteogenesis.20 These factors are regulators at different phases of
bone healing. For example, in phase 1 of healing, cells secret a large variety of signaling
molecules such as interleukins, fibroblast growth factors, and platelet derived growth
factors (PDGF) for the recruitment of inflammatory cells, fibroblasts, and repair cells that
initiate the other phases in bone healing.6, 12 Bone morphogenetic protein (BMP) and
fibroblast growth factor are the major signaling molecules for ossification or remodeling
soft callus into hard bone-like tissue.27 Angiogenesis or the process of new blood vessel
formation occurs in tandem to bone healing under the control of vascular endothelial
growth factor (VEGF) and the angiopoietin pathway.9 Cytokines including macrophagecolony stimulating factor (M-CSF) (haematopoietic stem cell) and receptor activator of
NFĸβ ligand (RANKL) regulate the resorption and regeneration of osteoclast and
osteoblasts.6, 20, 27

d. Osteoconductivity
To enhance bone regeneration, the scaffold should stimulate bone cell
differentiation, extracellular matrix deposition and mineralization. Natural ceramics
7

(calcium phosphate) and natural polymers (collagen fibers) are biomaterials native to
bone that have characteristics to encourage the bone cell attachment and vascular
infiltration.12 Scaffolds made from ceramics can provide the minerals needed for bone
cell mineralization. Furthermore, ceramic and collagen based scaffolds have good affinity
for proteins like glycosaminoglycans (GAGs) found in the cell membrane and
extracellular matrix.12

e. Biodegradability
The scaffold serves as a temporary support and template for bone regeneration at
the defect site. Ideally, the scaffold is replaced by bone tissue during bone formation and
regeneration through mechanisms that degrade or resorb the material.28 Degradation can
occur by different mechanisms such as hydrolysis, enzyme action, or a combination.29
However, the rate of degradation should correlate to the rate of bone formation so that
temporary structural support is replaced by the new bone tissue having load-bearing
capacity.30 The controllability of degradation is a goal for engineers to incorporate into
the design of synthetic bone substitutes.

f. Biomechanical
Bone has range of mechanical properties (cortical modulus: ~17 GPa, cancellous
modulus: 10-200 MPa), therefore, the scaffold must possess mechanical integrity similar
to cancellous bone to prevent collapse of the scaffold used in conjunction with an internal
device. The biomechanics of the scaffold correlates to the pore size, porosity, and rate of
degradation. The balance between porosity, degradation, and strong biomechanics
presents a challenge. At the initial time points of healing with little bone regeneration, the
8

scaffold strength should be equal or greater than that of the surrounding bone until new
bone can bear the load. Currently, bone scaffolds are used in conjunction with internal
fixation for fracture site stability to allow for good bone union and prevent collapse of
graft tissue site. The internal fixation can assist the scaffold by transmitting most of the
compressive load to encourage bone regeneration3. Scaffolds used in orthopedic
applications especially in long bone fractures should possess compressive strength similar
to that of cancellous bone (10-2000MPa).31

Biomaterials used in Tissue Engineering
Fabricating a bone scaffold to contain all these essential characteristics is a
significant challenge for researchers to overcome. However, with more understanding of
synthetic and natural biomaterials and the techniques to fabricate the scaffolds, ideal
synthetic bone substitutes will be engineered.
The most common biomaterials for scaffolds currently under investigation are
polymers, ceramics, and composites of both. These materials can be manipulated into
three-dimensional constructs with mechanical integrity, biocompatibility, and
osteoconductivity to promote specific cellular activities for bone healing and repair. The
architecture and functionality of the constructs can vary from sponges to injectable gels
to sintered microspheres depending on the material and techniques used.32 The variations
in biomaterials and fabrication methods allow for controllability in design specifics to
engineer scaffolds particular to orthopedic applications. Recent advancements showed
that the incorporation and controlled release of growth factors, cytokines, and other
molecular agents from scaffolds of varying materials have been shown to make materials
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osteoinductive thereby improving their bioactivity in facilitating localized bone
regeneration.11, 12, 33-37

a. Ceramics
Ceramics are inorganic and nonmetallic substances that have high compressive
strength due to the crystalline microstructure. Calcium phosphate, calcium sulfate, and
bioactive glass are some ceramics being examined as constructs for bone regeneration as
well as drug delivery vehicles because of their high binding affinity for proteins and
osteoconductive environment for host bone cells to regenerate bone.16 Calcium phosphate
and bioactive glass are biomimetic since they stimulate the production and deposition of
calcium phosphate in solution to improve integration during bone regeneration.16 Even
though calcium phosphate is a major component of bone’s mineral phase, it is still a
ceramic and when used alone its high resistance to deformation causes it to be brittle and
difficult to amend into strong porous constructs.38
In bone tissue engineering, calcium phosphate is commonly used as bone cement
due to its injectability, biomimetic characteristics, and osteointegration. The calcium
phosphate cement can be transformed into porous hydroxyapatite scaffolds using a
particle leaching method but its compressive strength is limited to ~6MPa which is
weaker than cancellous bone and prone to scaffold collapse.39, 40 The brittleness of the
calcium phosphate significantly lowers its compressive strength when porosity is
introduced. Therefore, calcium phosphate nanocrystals are commonly mixed uniformly
within the construct to enhance implant integration and bone healing while providing
compressive strength to provide mechanical support and maintain fracture space.23
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b.

Polymers

To avoid the brittleness of ceramics, some bone scaffold investigations focused on
polymers for its general material toughness. There are many synthetic polymers
(polylactide-co-glycolide (PLGA), polycaprolactones, polyanhydrides, etc) and natural
polymers (type I collagen, hyaluronic acid, and chitosan) that have been studied for use
as scaffolds for bone tissue engineering.36, 41-45 These polymers exhibit mechanical
stability, biodegradability, and ductility for bone tissue engineering. Some synthetic
polymers allow for controllability in degradation, porosity, and mechanical properties
while natural polymers provide better cytocompatibility and bioactivity. However, some
synthetic polymers have undesirable acidic degradation products and low
cytocompatibility while natural polymers have limited controllability in degradation and
mechanical strengths.43
For example, in a study performed by Wu and Ding, PLGA produced acidic byproducts. Three different compositions of PLGA were compared for mechanical strength
and molecular weight during degradation in phosphate buffered saline.43 Their results
showed that despite maintaining good compressive strength over the duration for the
study, the degradation of PLGA produced by-products causing a decrease in pH from
~7.0 to ~3.0, which raised concerns about decreasing cell viability.43 Consequently, to
improve biodegradation and cytocompatibility, Wu et al. coated PLGA scaffolds with
collagen and chitosan. The PLGA coated with collagen did improve degradation and
those coated with chitosan expressed higher ALP levels. The collagen coating made the
scaffold more hydrophilic inducing water absorption which increases the degradation of
the PLGA along with lactic and glycolic acid by-products. The PLGA coated with
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chitosan, on the other hand, supported osteoblastic expression of extracellular matrix in
human bone cells.46 Furthermore, PLGA is commonly used with a natural polymer or a
ceramic coating to enhance biodegradation, biocompatibility, and osteoconduction.43, 44, 46
Therefore, natural polymers with inherent biodegradability and biocompatibility
are of high interest for bone tissue engineering investigations. Chitosan is natural
polymer with favorable material characteristics for bone scaffolds including controlled
degradation, cationic properties for protein affinity, and solubility in dilute acids for
versatile matrix constructs.32, 47 However, chitosan does lack mechanical strength.
Consequently, to incorporate the advantage of the biomimetic and high compressive
property of ceramics, and the toughness and biodegradability of polymers, composite
materials of ceramic reinforced polymers are utilized to construct scaffolds with the
appropriate physiochemical and mechanical properties similar to that of bone.1, 3, 16

c.

Composites

Bone is composed of an inorganic mineral and an organic matrix phase organized
into a complex 3D hierarchy structure that no one material can purely be used to replicate
and mimic.31 Therefore, many bone scaffold designs have integrated osteoconductive
calcium phosphate ceramics with natural biodegradable polymers to simulate calcium
phosphate reinforced collagen bone composite.1, 4, 5, 17
For example, to improve compatibility of PLGA scaffold materials, Jiang et al.
constructed a microsphere-based composite (natural polymer to synthetic polymer)
scaffold of chitosan-poly (lactic acid glycolic-acid) (PLAGA). Chitosan was used to
provide enhanced compatibility while taking advantage of the strength properties of the
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PLAGA material. Compared to PLAGA alone the composite chitosan-PLAGA showed
enhanced differentiation of an osteoblastic cell line (osteoinduction).48
Most commonly, ceramics are used with polymer reinforcement to mimic the
collagen reinforced hydroxyapatite composite structure naturally found in bone.2 In a
study performed by Kim et al., the comparison of gas foaming/particle leaching (GF/PL)
to solvent casting/particle leaching (SC/PL) was determined in the fabrication porous
composite constructs of PLGA and hydroxyapatite (HA). The bone regeneration was
examined in vitro and in vivo for GF/PL, SC/PL, and PLGA with no HA scaffolds. The
study concluded that scaffolds fabricated using the GF/PL method had higher HA
exposure and in turn led to better bone formation compared to the SC/PL method by two
fold and PLGA without HA by ten-fold.41 However, the unattractive properties of
synthetic polymers namely acidic degradation products can over shadow for the
biomimetic ceramic and hinder the composite material in bone healing.
The use of a natural ceramic like calcium phosphate mineral toughened by a
natural polymer like chitosan may induce better mimicry because of its natural
biodegradability and biomimetic ability. Some studies have shown that integration of
calcium phosphate with chitosan had about a two-fold increase in compressive strength,
cell attachment, and matrix production.39, 45, 49-51

Composite Chitosan-Calcium Phosphate Scaffolds
Chitosan is the natural polymer of interest in this study due to its biocompatibility
(causes no inflammation and has antibacterial activity) and biodegradability (nontoxic
products of degradation).32, 47 Chitosan is the deacetylated derivative of chitin which is
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the major polysaccharide matrix polymer component of the exoskeleton of crustaceans,
insects, and some fungi. The chemical structure of chitosan is a linear β-(1-4)
polysaccharide consisting of glucosamine and N-acetyl glucosamine.47 The ratio of
glucosamine to N-acetyl glucosamine determines the degree of deacetylation (DDA). The
DDA ranges from 30-95% inversely related to degradation rate (e.g. the higher the DDA
the slower the degradation).32, 52
The amino and hydroxyl groups give chitosan its solubility in dilute acids
(pH<6.0) and cationic property which allow for the fabrication of various 3D matrix
forms with affinity for anionic molecules including glycosaminoglycans (GAG),
proteoglycans, proteins and biological agents.32, 53 Variability in fabrication techniques
can produce 3D constructs of many forms including injectable gels, sponges, porous
scaffolds, and microspheres that can serve as a drug delivery vehicle for osteoinductive
enhancements with growth factors, cytokines, and other biological agents.47 A study
conducted by Lee et al., used chitosan sponges loaded with platelet-derived growth
factor-BB to demonstrate the osteoconduction and osteoinduction of the chitosan matrix
in an in vitro and in vivo evaluation.54 These intrinsic material properties of chitosan are
of high interest in bone tissue engineering scaffold design and fabrication.
In bone tissue engineering applications, chitosan is commonly used as a
composite with calcium phosphate since both are biocompatible, and osteoconductive,
and the calcium phosphate can provide strength while the chitosan provides toughness.16,
32

For example, in a comparison of pure chitosan and composite chitosan-calcium

phosphate sponge (chitosan based with powder calcium phosphate particles), a two-fold
higher compressive strength and 1.5 improvement in cell proliferation and mineralization
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was exhibited for the composite sponge.49 Xu et al. constructed macroporous chitosancalcium phosphate scaffolds (calcium phosphate cement based with 1-2% chitosan) with
the fast setting capability that could facilitate better bone tissue and implant integration in
vivo compared to calcium phosphate cement alone.55 These studies produced scaffolds
exhibiting good pore sizes ~50-120µm (Thien et al.) and porosity 52-75% (Xu et al.)
along with improvement in mechanical properties with maximum compressive modulus
at ~9KPa (Thien et al.) and scaffold strength of 0.3MPa at 65% porosity (Xu et al.).49, 55
However, overall mechanical properties remained low when compared to the
compressive strength of cancellous bone 10MPa to 2000MPa since there was no direct
bonding of calcium phosphate to chitosan chains for mechanical reinforcement.
To improve mechanical properties, a microsphere-based scaffold design based on
nanocrystalline calcium phosphate particles homogenous with chitosan have been
made.45, 50 The architectural design of a microsphere-based scaffold with interconnected
pores relies on the fusion of uniform microspheres, which allows for shape and size
versatility. This expands the uses of the composite chitosan-calcium phosphate scaffold
to a range of orthopedic applications including craniofacial augmentation and long bone
fractures. When the microspheres are fused together, a network of interconnected pores
are produced to serve as a negative template for efficient nutrient and waste exchange,
vascular formation, mechanical integrity, and tissue infiltration. However, current
microsphere designs of PLGA and chitosan use a sintering process that exposes the
scaffolds to high heat for extended periods, which would alter molecular structure of
chitosan. Also the fused connections between the beads were cracked leading to loss of
mechanical strength.56 Therefore, the composite chitosan and calcium phosphate
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microsphere produced from a co-precipitation method can be fused by partially
dissolving the surfaces of the microspheres and also eliminate the harsh processing
conditions and could improve the fusion between the microspheres.
The calcium phosphate and chitosan are co-precipitated in chitosan matrix to
mimic natural organic-inorganic structure of bone. The study conducted by Chesnutt et
al. showed that the calcium phosphate is uniformly incorporated within the scaffold
microspheres in the nanocrystalline form to enhance compressive strength for load
bearing.45 The composite scaffold exhibited a two-fold increase in compressive modulus
along with better cell proliferation and matrix deposition as indicated by increasing trend
in ALP and total protein as opposed to the chitosan scaffold. However, the solid
homogenous microsphere alone had slow degradation and low porosity that could not
simulate the architectural difference of cortical and cancellous bone. In a follow up study
conducted by Reves et al., the composite microspheres were lyophilized and exhibited a
four-fold increase in surface area, a 50% increase in porosity, and a high absorption
potential which could contribute to faster degradation.50
The scaffold used in this study will incorporate two types of microspheres with
different physical properties formed through two different drying methods – air-dry and
lyophilization. The air-dried (AD) microsphere is a solid providing compressive strength
and prolonged degradation while the lyophilized (FD) microsphere is hollow, light, and
microporous with increased surface area contributing to faster degradation and protein
adsorption.45, 50 Combinations of these microspheres in different shapes and sizes have
the potential to be versatile constructs improving bioactivity for numerous clinical
applications in orthopedics.
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Summary
Critical size bone fractures and defects that exceed innate physiological healing
processes of bone require surgical intervention to induce bone healing utilizing a bone
graft.8, 17 Autografts and allografts are the most clinically used bone grafts; however,
there are limitations associated with their use including limited quantity and loss of bone
physiochemical properties. Consequently, bone tissue engineering endeavors focus on
designing scaffolds that mimic the regenerative capacity of bone. Researchers investigate
the combination of ceramics, polymers, and their composites to produce scaffolds with
the biocompatibility, 3D architecture with interconnected pores, biodegradation,
osteoconduction, osteoinduction, and biomechanics similar to bone. The scaffold serves
as a temporary negative template with mechanical and biological support for bone
formation. A composite of chitosan and calcium phosphate microsphere based scaffold
has shown much promise as a bone engineering scaffold since it has advantages of
cytocompatibility, biodegradability, osteoconduction, and mechanical properties, though
the solid composite microspheres did not exhibit ideal degradation and porosity.45
Lyophilized microspheres were demonstrated to increased scaffold surface area and
porosity which could lead to increased degradation. Therefore, it is hypothesized that
using a combination of lyophilized and solid microspheres of chitosannanohydroxyapatite will improve scaffold degradation without compromising mechanical
or osteogenic properties.
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CHAPTER 2: OBJECTIVES AND SIGNIFICANCE
It is hypothesized that using a combination of lyophilized and solid microspheres of
chitosan-nanocrystalline calcium phosphate will improve scaffold degradation
without compromising mechanical or osteogenic properties
To test this hypothesis the following specific objectives were undertaken:

Objective 1
Design and construct three-dimensional cylindrical chitosan-nanocalcium
phosphate microsphere based scaffold for bone tissue engineering using two varieties of
composite microspheres (freeze-dried, FD and air-dried, AD). The AD microspheres are
used to form an outer surface to provide strength to the scaffold with the interior surfaces
composed of the freeze dried microspheres, which provide increased surface area,
porosity and degradability. This hierarchical arrangement is used to mimic long bone
organization with the AD providing the hard outer shell and the FD the spongy middle
similar to cortical and cancellous bone, respectively. The first steps are to
a) Create a mold for microsphere fusion having a cross sectional area similar to the
long bone.
b) Determine the optimal ratio of FD to AD with in the limits of the mold.
c) Develop a process and technique to fuse FD and AD microspheres.
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Objective 2
Evaluate the ability of bone cells to attach, grow and elaborate bone matrix on
scaffolds in vitro. For this objective,
a) Bone cell growth will be measured based on DNA quantification.
b) Alkaline phosphatase (ALP) activity will be measured for bone phenotype and
total collagen levels for extracellular matrix production.
c) Scanning electron microscopy (SEM) will be used to qualitatively view cells and
elaborated matrix on scaffolds.

Objective 3
Characterize the biomechanics and biodegradability of the scaffolds during in
vitro enzymatic degradation. Degradation and compressive modulus is obtained by
a) Mass change of AD and FDAD scaffolds.
b) Compression testing of both scaffold types to obtain the compressive modulus.

Significance
This research will provide data on the potential of using a combination of airdried and freeze-dried microspheres to construct a bone scaffold to mimic the cortical and
cancellous architecture of bone, and provide favorable structures for bone cell growth and
matrix production while maintaining mechanical strength and enhancing degradation.
The results of this work, if successful, will provide the foundation for additional scaffold
design studies in vivo, for bone graft use, use in drug delivery, and clinical applications.
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Abstract
Chitosan nano-hydroxyapatite composite microsphere based scaffolds have
exhibited mechanical and osteoconductive properties favorable for use as a bone graft
substitute material. However, the degradation of the scaffold has been limited. By
incorporating lyophilized microspheres to the scaffold construct, scaffold porosity can
increase leading to an increase in scaffold degradation. In this study, scaffolds were
constructed from solid air-dried and lyophilized composite chitosan-calcium phosphate
microspheres and were evaluated in vitro for cell behavior and mechanical properties.
The combination scaffold composed of air-dried and lyophilized microspheres (FDAD)
was compared to the air-dried scaffold (AD). It was hypothesized that the addition of
lyophilized microspheres (FD) would improve scaffold degradation without
compromising the osteogenic and mechanical properties of the scaffold. Mineralization
results showed FDAD had 80% higher cell number (p<0.01) and 31% greater collagen
elaboration as compared to AD. However, the addition of FD microspheres did
compromise the mechanical properties decreasing the compressive modulus by 60%
without increasing scaffold degradation. These results indicate FDAD scaffolds have
more osteogenic potential based on cell growth and collagen elaboration, but AD
scaffolds demonstrated higher compressive strength. Even though results did not support
the stated hypothesis, further investigations to improve scaffold strength will be
conducted for this osteogenic construct.
Keywords: chitosan scaffolds, chitosan microspheres, degradation, compression,
mineralization
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Introduction
As the ≥65 age group reaches its projected 51.5 million in 2020, the number of
age-related fractures will significantly increase the current yearly demand of 500,000
bone grafts.1, 2 Surgical treatment for bone fractures and defects commonly utilize
autografts and allografts. Autografts are bone tissue commonly retrieved from the
patients’ own iliac crest; however, the quantity and quality of the bone from aged patients
are low.3 Allografts are donor bone tissues that have been decellularized to remove all
bacterial and viral diseases along with some innate physiochemical and mechanical
properties.3-5 Bone tissue engineering approaches are focused on engineering synthetic
scaffolds that can mimic the physiological functions of bone. The scaffolds are
engineered to induce osteogenesis by providing a three-dimensional (3D) support
environment favorable for osteoblasts to grow, proliferate, and form new bone
formation.6-8 The scaffolds serve as functional templates for bone regeneration, provide
temporary support within the fracture gap, and are integrated into the body during bone
healing and formation.
The current composite materials of high interest are incorporate calcium
phosphate, native to bone, with chitosan because of its unique biomaterial properties
favorable for bone tissue engineering. Chitosan is a natural polymer, derived from partial
deacetylation of chitin, which is a polysaccharide found in the exoskeleton of crustaceans
and insects.9, 10 The polysaccharide backbone and amino side groups give chitosan its
unique properties of controlled degradation, protein affinity, and acidic solubility.8-10
Chitosan combined with calcium phosphate in different scaffold designs support
increased cell proliferation and mineralization when compared to chitosan and ceramics
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alone.11-13 Xu et al. constructed a macroporous scaffold from a composite of injectable
calcium phosphate cement (CPC) and 1-2% of chitosan that showed improved implant
integration compared to CPC scaffolds alone but it had limited compressive properties
(9MPa at 20% macro-porosity and 2.5MPa at 40% macro-porosity) and degradation was
undetermined.13 In a different macroporous scaffold design, Thein-Han et al.
demonstrated that composite chitosan sponge scaffolds incorporating powder calcium
phosphate enhanced cell attachment, proliferation, and good cell morphology with 1529% degradation but it also had limited compressive properties (maximum ~9KPa).11
Chesnutt et al. incorporated nanocrystalline calcium phosphate with chitosan through a
co-precipitation method to produce composite microsphere based scaffolds that exhibited
better bone cell proliferation and mechanical properties (~9MPa closer to minimal
cancellous strength) than scaffolds constructed from chitosan microspheres.14-16
However, there was no significant mass change for both scaffold types possibly due to
the degree of deacetylation and crystallinity of chitosan and even density of
microspheres.14 In a follow-up study, Reves et al. demonstrated that the surface area,
porosity, and absorption of the composite chitosan-calcium phosphate microspheres
could increase with lyophilization which could lead to better degradation.17
The aim of this study is to combine freeze-dried (FD) composite microspheres
with solid air-dried (AD) composite microspheres to construct a scaffold that mimics the
architecture of long bone while providing mechanical support (10-2000MPa) at the
fracture site. It is hypothesized that incorporating FD microspheres will improve scaffold
degradation without compromising the mechanical and osteogenic properties.
Combination scaffolds (FDAD) of organized FD and AD microspheres were constructed
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for in vitro mineralization and degradation evaluation to determine osteoblastic
attachment and proliferation, scaffold osteoconduction, and compressive modulus change
during degradation. All AD scaffolds were used as controls.
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Materials and Methods
Fabrication of Composite Chitosan Calcium Phosphate Microspheres
Composite microspheres were produced through a co-precipitation method.14
Briefly, 87.4% DDA chitosan and calcium phosphate were dissolved in 2% (v/v) acetic
acid for 24 hours. Then the solution was filtered through a 200µm nylon mesh to remove
any large particulates. The microspheres were formed through a co-precipitation process
in which the solution is added drop-wise to a strong base solution (50 wt% of distilled
water, 30 wt% methanol, and 20 wt% sodium hydroxide). The microspheres were stirred
in the base solution for 24 hours to allow for the formation of calcium phosphate
nanoparticles. The batch of microspheres was washed with deionized (DI) water with
constant stirring and water replacement until the pH reached 7.5-8.0. The microspheres
were then dried by two different methods: air-dried and lyophilized (freeze-dried). For
the air-dried method, the microspheres were spread out in a single layer and allowed to
dry in a fume hood. For freeze-dried method, a majority of the moisture was removed
from the microspheres before placing them sparingly on dishes to freeze in the -80ºC
freezer. Once the microspheres were frozen, after an hour, they were transferred to the
lyophilizer (FreezeZone 2.5, Labconco) to freeze-dry overnight.

Fabrication of Scaffolds
The washer-shaped scaffolds were formed by fusing microspheres in a circular
mold. The combination scaffold (FDAD) had an outer ring of air-dried (AD)
microspheres and an inner ring of freeze-dried (FD) microspheres. The all air-dried
scaffolds consisted of only air-dried microspheres. The amount of microspheres for each
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scaffold was weighed for consistency both in mass and size. The AD scaffolds were
made with 0.610±0.005g of AD microspheres while the FDAD scaffolds consisted of
0.290±0.005g of AD microspheres and 0.080±0.005g of FD microspheres. To fuse the
microspheres, about 3-4 drops of 1% acetic acid was used to partially dissolve the surface
of the microspheres to make the microspheres adhere to each other. The acid rinsed
microspheres were transferred to scaffold molds. The molds were made with ~7mm thick
cross sections from 15ml centrifuge tubes (FisherBrand). The molds containing the
microspheres were air-dried in a fume hood to remove excess acid.

Scaffold Architecture
Scaffold dimensions (height, outer diameter, wall thickness) were measured using a
caliper before compression in the hydrated state. The architecture and surface topography
was also examined under SEM.

Cell Culture
Both scaffold types were sterilized using low dose gamma irradiation (25-32
kiloGreys) and then soaked in medium to neutralize any residual acid for 2 days before
use with cells. The human sarcoma cell line (Saos-2; ATCC HTB-85) was used to
evaluate the ability of the scaffolds to support bone cell growth and matrix production.
Approximately two million cells were seeded onto the scaffolds using mineralizing
medium (McCoy’s 5A Medium with 10mM of β-glycerol phosphate, and 50µg/mL of
ascorbic acid in addition to 10% fetal bovine serum and 1% antimycotic and antibiotic
(Fisher, Penicillin-10,000 IU/mL, Streptomycin-10mg/mL, Amphotericin B-25µg/mL).
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The medium was changed every 2 or 3 days for 28 days. Representative samples (n=4) of
both scaffolds were collected at days 1, 7, 14, 21, and 28 for cell proliferation, amount of
ALP, and extracellular collagen measured.

Cell Proliferation
To confirm cell attachment, growth, and proliferation, cell number was measured
via DNA quantification for day 1, 7, 14, 21, and 28 for both sample types (n=4).
Scaffolds were collected at random for each time point and transferred to new well plates
and ultrasonicated for ~10 seconds per side with 2mL of sterile water (Fisher Scientific).
The lysate was used for measuring DNA using the Picogreen (Invitrogen, Eugene, OR)
assay and alkaline phosphatase activity. The Picogreen reagent is a nucleic acid stain for
quantitating double-stranded DNA (dsDNA) in solution, which would correspond with
cell number. The concentration of the nucleic acids was determined at an absorbance of
260nm. DNA was reported normalized to scaffold mass. For visual verification,
Live/Dead® staining was used for both sample types (n=1). The reagents of the
Live/Dead® are calcein, which causes live cells to fluoresce green under blue light, and
Eth D-1, which causes dead cells to fluoresce red under green light. The scaffolds with
stained cells were viewed using a Nikon Eclipse TE300 with mercury lamp (Southern
Instruments, GA) and images recorded XCCD camera and the BioQuant Osteo II
software (Nashville, TN) to visualize cell viability and distribution.
Alkaline Phosphatase Activity and Hydroxyproline Content
The lysate collected from scaffolds (n=4) at each time point was used to measure
alkaline phosphatase (ALP) enzymatic activity for osteoblastic phenotype expression.
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ALP was measured based on the hydrolysis of p-nitrophenyl phosphate following Sigma
ALP protocol. Absorbance measurements were taken at 405nm. The ALP activity was
computed from the standard curve with duplicates averaged. Amount of ALP normalized
to DNA was reported with standard deviations for days 1, 7, 14, 21, and 28.
Collagen concentration was determined by quantifying hydroxyproline, a major
component of collagen making up 12.5% of the dry weight of the structural protein. The
method used was a modified version of that described by Reddy and Enwemeka18.
Representative samples (n=2, replicates were reduced due to loss of samples) of both
scaffold types were collected and weighed to normalize hydroxyproline to scaffold mass
(µg of collagen/ g of scaffold). The samples were transferred into microcentrifuge tubes
(Thermo Fisher Scientific, Inc.), which contained o-rings inside the caps to withstand
positive pressure. Teflon tape was also applied to the threads of tubes for reinforcement.
Amino acid hydrolysis was conducted using 1.5 mL of 6M HCl into each tube and the
tubes placed inside a high heat resistant glass bottle to equalize pressure during the
incubation at 110°C overnight. The samples were allowed to cool before they were
centrifuged for 10 minutes at 14,000 RPM to separate the particulates from the aqueous
solution containing the hydroxyproline. The 1mL of the aqueous solution was transferred
to 25mL Erlenmeyer flask with 4mL of DI water. The samples were then prepared for
lyophilization to concentrate the hydroxyproline. Lyophilization was repeated once more
after rehydrating with 4ml of DI water to reduce the acidity. Additionally, hydroxyproline
(Sigma-Aldrich) standards were made in DI water and subjected to hydrolysis. Each
supernate (25µl) was tested in duplicates using the chloramine-T oxidation of
hydroxyproline to a pyrrole derivative followed by chromogen production with the
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addition of Erhlich’s reagent in a 96-well culture plate. Absorbance measurements were
taken at 550nm using a SpectraMax® Plus384 spectrophotometer (MDS Analytical
Technologies, Inc., Toronto, Canada). Background measurements taken at 550nm were
subtracted and standard curves were generated to determine unknowns. Specimen values
were taken as the average of the duplicates.

Extracellular Matrix Production
SEM images were qualitatively examined for cell proliferation, morphology and
matrix production. Samples for the SEM were prepared according to protocol by soaking
the scaffolds in 4% formalin overnight and into consecutive ethanol solutions 70, 80, 90,
and 95% for 15 minutes each and then twice in 100% ethanol for 1 hour. The scaffolds
were sputter coated with 70nm of gold and platinum to be viewed in environmental SEM
(Philips ESEM30) at 30kV.

Enzymatic Degradation
In vitro degradation was simulated using a lysozyme and sterile DI water solution.
Initial dry mass (mg) of AD and FDAD scaffolds was obtained before the scaffolds were
packaged for gamma irradiation. The scaffolds were contained in a 12-well plate then
soaked in 3mL of 100µg/ml lysozyme (MP Biomedicals, OH) in water. The lysozyme
solution was changed every 2 days. Samples (n=4) of AD and FDAD were collected at
days 1, 7, 14, 21 and 28 and compression testing was conducted before final dry weight
was obtained (see section 3.3.9). Once the scaffolds were mechanically tested, the
scaffolds were placed into a vacuum oven to dry under vacuum pressure of 15psi and at a
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temperature ~37°C for 5 days. Percent change in mass was calculated based on the initial
pre-sterilization dry mass and final dry mass of compressed scaffolds (dried under
vacuum at 37°C).

Compression Testing
Compression testing was conducted using an Instron mechanical testing machine
(Model: 33R, MA) and the integrated Bluehill software. Hydrated scaffolds collected
during days 1, 7, 14, 21, and 28 of degradation (n=4) were compressed under a 5kN load
cell at a controlled rate of 1mm/min until 50% compressive strain. Testing specimen was
specified as tubular (outer diameter, wall thickness, and height) and dimensions for each
cylindrical scaffold were used. Compressive modulus and compressive stress at 50%
strain were determined using the Bluehill software. Data were collected at days 1, 7, 14,
21, and 28 of degradation.

Statistical Analysis
This study compared AD scaffolds versus combination FDAD scaffolds using
two-factor (scaffold type, time) ANOVA (Microsoft Excel) with SNK post-test to
determine significance and differences. Significance was declared at p<0.05.
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Results
Scaffold Architecture
Consistency and similarity in the shape of each microsphere type and dimensions
within the scaffold types can be seen in the dimension data (Table 1). The scaffolds are
cylindrical in shape with a hollow center core. The FDAD scaffold has an outer shell of
AD microspheres and an inner core of FD microspheres to simulate the arrangement of
long bone.
The orange arrow in Figure 1 demonstrates the surface area where two AD
microspheres were fused together. This area is difficult to see on FD microspheres due to
the textured surface. Microsphere surface topography is apparent at 25x magnification
under SEM. SEM micrographs show a smooth surface for AD microspheres and the
textured surface of the FD microsphere. Sectioned AD microspheres show homogenous
core while the FD microspheres are porous (Figure 1).

Table 1. Summary of Scaffold Dimensions (mm)
Parameters
Outer Diameter
Wall Thickness
Height

AD Scaffolds (n=20)
15.86 ± 0.13
5.63 ± 0.14
7.33 ± 0.04

FDAD Scaffolds (n=20)
14.94 ± 0.12
5.13 ± 0.14
6.81 ± 0.17

AD scaffolds – scaffolds constructed from solid air-dried microspheres
FDAD scaffolds – scaffolds constructed form solid air-dried and freeze-dried microspheres
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Figure 1. Images of the AD scaffold (left) and FDAD combination scaffold (right) are
shown. At 25x, the SEM images show the smooth surface of air-dried (left) microspheres
and the highly rough topography of the lyophilized microspheres (right). Orange arrow
points to fusion area between two microspheres. Cross sections of AD and FD
microspheres at 100x shows the interior solid and hollow core, respective.
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Qualitative Microscopy
Live/Dead® images show live cells as green and dead cells as red. Few dead cells,
that indicated high cell viability, was present on all scaffolds at all time points. Based on
fluorescent images, similar cell attachment and proliferation were seen for both scaffold
types at all time points at 40x magnification. Saos-2 cells appeared to localize at
microsphere contact points on the AD scaffolds indicated by the white arrows (Figure 2).
The textured surface of the freeze-dried microspheres in the FDAD scaffolds created a
favorable environment for cell attachment across the surface.
SEM images show cell mophology varied from elongated and flat to circular and
spherical (Figure 3). The variation in cell morphology can be seen uniformly throughout
the scaffold at all time points and with no preference to area. Minimal matrix deposition
on the scaffolds over the 28 day cultures was seen via SEM examination (Figure 3).
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Figure 2. Fluorescent images of scaffolds stained with Live/Dead® to show green
fluorescing live cells and red fluorescing dead cells at 40x magnification. Representative
fluorescent images are overlay images of the sample under green and red fluorescence.
White arrow indicates microsphere contact point with high cell concentration.
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Figure 3. SEM images of AD and FDAD scaffolds at different time points of
mineralization. Variation of cell morphology can be seen at 500x magnification.

DNA quantification and ALP Activity
Two-factor ANOVA indicates a difference in DNA concentration over time
(p<0.001) and between scaffold types (p<0.001). Post-hoc analyses indicate that FDAD
scaffolds had significantly higher cell number (~31%) than AD scaffolds at all time
points (Figure 4). For FDAD scaffolds, cell number remains relatively constant from day
1 to 7, increases significantly from day 7 to 14, plateaus between day 14 and 21, and then
decreases slightly but not significantly at day 28. For AD scaffolds, while there was a
trend for increasing cell number over 28 days, increases were not statistically significant.
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Figure 4. DNA concentration is an indicator of the number of cells during 28 days of
mineralization. DNA is normalized to scaffold mass for comparison between the two
scaffold types. There is a significant difference between scaffolds types (p<0.001) at all
time points. + Significantly different from other days except day 1, * Significantly
different from days 21, and 28.

Two-factor ANOVA of ALP levels indicates a difference in ALP levels over time
(p=0.002) but no difference between scaffold types. Post-hoc analyses reveal significant
changes in ALP levels only for FDAD scaffolds (Figure 5). ALP levels decrease from
day 1 to 7, increase significantly from day 7 to 21, and then decrease slightly but not
significantly from day 21 to 28. For AD scaffolds, while there was a similar trend in ALP
levels over the 28 days, changes were not statistically significant.
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Figure 5. Alkaline phosphatase activity normalized to DNA concentration for osteoblast
phenotypic expression. No significant difference between scaffold types. There is a
significant difference over time (p=0.002). + Significantly different from other days
except 14. * Significantly different from days 21 and 28.

Hydroxyproline Content Normalized to Scaffold Mass
Total collagen based on determination of hydroxyproline production on AD and
FDAD scaffolds exhibits no difference over time but a difference between scaffold types
(p=0.0067) (Figure 6). On average, 80% more collagen was produced on FDAD scaffolds
than on AD scaffolds. However, cells on the FDAD scaffolds was ~31% greater than on
the AD scaffolds.
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Figure 6. Hydroxyproline content measurements during mineralization as an indicator of
collagen synthesis. Significant difference between scaffold types (p=0.0067).

Degradation and Compression
Data on the degradation of the scaffolds based on change in mass is shown in
Figure 7. Graph shows mass gain (positive percent) and mass loss (negative percent). The
pattern of mass change is irregular and standard deviations are wide. At day 1, the AD
scaffolds exhibited 2-17% range of mass gain as opposed to the 2-4% mass gain of the
FDAD scaffold. Then at day 21, mass of AD scaffolds had no change to a 6% loss in
mass. By day 28, there was mass gain. Consequently, there were no difference between
scaffold types and with time.
Compressive strengths for both scaffolds exhibit no significant change over time.
However, as shown in Figure 8, the compressive moduli for AD scaffolds were
significantly higher than the FDAD scaffolds (p<0.001)) (Figure 8). At day 7, AD
scaffolds demonstrated a maximum average modulus of 12.5±2.8 MPa as oppose to
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FDAD scaffolds with an average of 2.2±1.4 MPa. Over the 28 days of degradation, the
compressive moduli of both scaffolds showed no significant change.
During compression testing of the FDAD scaffolds, visual observation of the stress
and strain curve showed an initial rise in the stress strain curve supported by the exterior
shell of AD microspheres and slight decrease in stress when the AD shell was broken.
Figure 9 showed a FDAD scaffold before and after compression. The outer AD
micropshere shell was permanently deformed while the interior FD microspheres
exhibited no permanent deformation.

Degradation by Mass Change

Percent Mass Change (+increase, decrease)

15%
AD

FDAD

10%

5%

0%

-5%
Day 1

Day 7

Day 14

Day 21

Day 28

Figure 7. Mass change of AD and FDAD scaffolds (n=4) during enzymatic degradation
for 28 days. No significant difference between scaffold types and with time.
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Figure 8. Compressive modulus of scaffolds (n=4) at different time points of lysozyme
degradation. There is no change in compressive modulus for bone scaffold types.
Significant difference between scaffold types (p<0.001).

Figure 9. FDAD scaffolds before and after compression testing. The exterior AD
microspheres were deformed while FD interior had no permanent deformation.
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Discussion
Composite chitosan-calcium phosphate marcoporous scaffolds produced by Xu et
al. and Thien-Han et al. were composite mixtures based on CPC with small amounts of
chitosan and chitosan based with powder calcium phosphate particles, respectively.11, 13
The scaffold mechanical properties were characterized and results demonstrated a
flexural strength of ~9MPa at 20% macro-porosity and ~2.5MPa at 40% macro-porosity
(Xu et al.) and a compressive modulus of ~9KPa (Thien-Han et al.) which is low when
compared to the porosity (75-95%) and compressive modulus (10-2000MPa) of
cancellous bone.11, 13, 15 The composite microsphere-based scaffolds produced by
Chesnutt et al. provided compressive strength (~9MPa) and porosity (33-35%) more
similar to cancellous properties. However, the microspheres exhibited no mass loss
during 14 days of enzymatic degradation.14 Reves et al. produced freeze-dried
microspheres and constructed a microsphere-based scaffold with increased porosity by
50% and surface area by 400% as compared to an all air-dried scaffold similar to those
constructed by Chesnutt et al.14, 17
To take advantage of the mechanical properties of the microsphere-based
composite chitosan calcium phosphate scaffolds and the increased porosity, and surface
area of the freeze dried microspheres, this study created a novel scaffold design
incorporating both solid AD and hollow FD microspheres for mechanical stability and
increased surface area for more efficient degradation. The design of the scaffold is similar
to that of a cross section of long bone. The scaffold was evaluated via in vitro
mineralization and degradation to determine osteoblast growth and mineralization, and
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compressive modulus change during degradation. Results were compared to all AD
microsphere based scaffolds.
FDAD scaffolds supported growth and expression of bone cells, markers, and
matrix proteins during 28 days of in vitro mineralization. Furthermore, FDAD scaffolds
showed 31% higher cell number per scaffold mass leading to an 80% greater collagen
elaboration per scaffold mass as compared to AD scaffolds. Cell numbers were higher
because FD microspheres had textured surfaces and hollow cores, which are indicative of
increased surface area and decreased density, respectively. While cells elaborated
collagen and cells on FDAD elaborated more collagen than AD scaffolds, significant
mineralized matrix was not observed on scaffolds similar to what others have seen.11, 14, 19
Cell to cell contact is critical to matrix production and mineral deposition but cells were
not confluent on the scaffolds which could hinder mineralization.
The low cell confluence may also be the reason to delayed peak ALP expression
on the scaffolds as compared to past studies. Typically, ALP peak occurs around day 714 of mineralization but in this study the peak was not seen until day 21.20 Since the peak
ALP expression is associated with the onset of mineralization, the delay in expression
would be indicative of why extensive mineralized matrix was not observed within the
study time frame.
The degradation of the scaffolds as estimated by change in mass did not reveal
any substantial change in scaffolds. Similarly, there were no changes in mechanical
properties of the scaffolds over time. These data would suggest that despite the presence
of lysozyme in solution, there was little if any degradation of the scaffolds. The low
degradation may be attributed in part to the relatively high degree of deacetylation
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(DDA) of the chitosan. Chitosans with high DDA typically have high crystallinity, and
show resistance to enzymatic attack hence the higher the DDA the slower the
degradation. Even with the addition of FD microspheres, FDAD exhibited minimal mass
loss. However, this may also be an issue with the measurement for mass loss since initial
moisture content of scaffolds were not controlled prior to starting experiments. Also,
even if FD microspheres degraded, relative change in mass may not be easily determined
by mass loss. However, minimal loss in mass and mechnical properties over the 4 weeks
may be advantageous since only newly formed, immature bone is regenerated within that
time frame, hence, without sufficient mechanical integrity additional support is required
to prevent collapse of the scaffold and new bone. A longer degradation study could
determine when degradation is initiated along with mechanical loss. Jiang et al.
demonstrated that the sinter PLGA and chitosan microspheres had no dramatic decrease
in mass, molecular weight, or mechanical strength after 12 weeks even though the in vivo
rabbit study showed good bone formation for the composite scaffolds.21 The FDAD
scaffold design did not improve degradation but it did improve cell attachment and
collagen prodution.
Jiang et al. constructed scaffolds based on sintered composite PLGA-chitosan
microspheres reported a compressive modulus ranging from ~220-440 MPa (hydrated or
dry was not stated) depending on the temperature and duration of sintering.22 Chesnutt et
al. used similar composite chitosan calcium phosphate microspheres to construct
scaffolds having a maximum modulus of 9.28 MPa when hydrated and 117.57 MPa when
dry.14 This study only conducted mechanical testing on hydrated scaffolds but in a follow
up study compression testing should be conducted for the dry scaffolds to determine how
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much mechanical strength is loss during hydration and also to compare to dry and
hydrated bone strength. The hydrated AD scaffolds demonstrated similar compressive
modulus of 9.5 MPa which is comparable to that of cancellous bone (10-2000 MPa)
while FDAD scaffolds exhibited an average modulus of 2.1 MPa. The inner FD
microspheres were elastic due to its porous structure since no permanent deformation was
seen after compression. As for the AD scaffolds, the microspheres after compression
were separated from one another but more so after day 7. Consequently, the fusion
between FD micropsheres as opposed to AD microspheres were stronger and more
intergrated. Even though the addition of FD microspheres reduced mechanical strength,
fracture treatments use bone grafts in conjunction with internal fixation devices to
transmit the majority of the load. Furthermore, incorporating FD microspheres showed an
improvement in osteoconduction.

Conclusion
In this study, FDAD scaffold design incorporated air-dried and freeze-dried
composite chitosan calcium phosphate microspheres to provide mechanical support
similar to cancellous bone, and degrade without substantial loss in mechanical integrity.
Both scaffolds exhibited cytocompatibility but FDAD scaffolds allowed for higher cell
number per scaffold mass. Consequently, FDAD scaffolds had higher total collagen
production based on scaffold mass than AD scaffolds. The degradation of AD and FDAD
scaffolds over a 4 week test period in lysozyme was minimal. In compression testing, the
AD scaffolds exhibited greater compressive strength than FDAD scaffolds. Even though
the incorporation of FD microspheres compromised mechanical integrity of the FDAD
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scaffold, osteogenic properties were improved with higher cell population and production
of collagen content as compared to scaffolds with AD scaffolds. Future studies will focus
on characterizing pore size, porosity, and surface, improving the rate of degradation, and
maximizing compressive modulus of the combination FDAD scaffolds to serve as bone
graft substitutes.
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CHAPTER 4: SUMMARY AND CONCLUSIONS
In the United States, over 500,000 patients are in need of bone grafts for a variety
of orthopedic complications including bone fractures and defects.5 To meet clinical
demands, bone tissue engineering investigates synthetic three-dimensional matrix to
provide structural support and tissue guidance.3, 17, 22 Scaffolds constructed from
biomaterials must have suitable biomechanical properties and 3D macro- and microstructure to be physiologically functional and support tissue infiltration and growth.1, 3 An
ideal scaffold should elicit appropriate host responses, degrade at a rate similar to that of
bone regeneration, maintain mechanical integrity, have interconnected pores for nutrient
and waste exchange, promote bone cell attachment and proliferation, and facilitate bone
formation.1, 3-5, 31, 32 Current bone scaffolds constructed from polymers, ceramics, and
composites have not met the challenge with their low mechanical properties,
biodegradability, and degradation rates.1, 4, 24 The primary objective of this research was
to fabricate a composite chitosan-calcium phosphate scaffold based on air-dried and
freeze-dried microspheres possessing essential design criteria including high porosity
with interconnected pores for bone matrix and blood vessel ingrowth, compressive
strength for load bearing, and surface chemistry promoting bone tissue growth and
organization as an ideal bone graft substitute.
The composition of chitosan with nanoparticle calcium phosphate mimics the
inorganic and organic composition of bone which is a synergistic pairing of a natural,
biodegradable, and biocompatible polymer with a biomimetic, biomechanical, and
osteoconductive bone mineral calcium phosphate.1, 4, 5, 17, 32 Chitosan is polysaccharide
consisting of glucosamine and N-acetyl glucosamine with free amino and hydroxyl side
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chains for protein affinity.32 Calcium phosphate is a major mineral component of bone
with the innate capacity to conduct bone cell attachment, proliferation, and
mineralization.16 Chitosan is the organic matrix that can uniformly encapsulate calcium
phosphate nanoparticles for a functional composite bone scaffold material.45, 50
A co-precipitation method was utilized to produce microsphere composite of
chitosan and a bioceramic calcium phosphate.45, 50 Scaffolds consisting of air-dried (AD)
and freeze-dried (FD) microspheres or entirely of all air-dried microspheres were
compared for mechanical and degradation properties, and ability to support bone cell
growth and matrix production in vitro. The AD and FD microspheres were arranged to
mimic the cross section of long bone. The AD scaffolds were constructed entirely of AD
microspheres while the FDAD combination scaffolds were solid AD microspheres lining
the outer shell and the microporous FD microspheres filling the interior shell.
The surface topography and microsphere density of FD microspheres was
textured and porous as opposed to the smooth surface and homogenous solid core of the
AD microspheres. Reves et al. showed that the addition of FD microspheres increased
surface area by 400% and porosity by 50%.50 This provided an advantage for FD
microspheres for uniform distribution of cells along with 30% increase in cell number per
scaffold mass that led to the 81% greater production of total collagen per scaffold mass.
However, the incorporation of the FD microspheres to the interior of the scaffold
decreased the mechanical strength by 60%. Even though compressive strength was
weakened, the addition of FD microspheres that are microporous with textured surface
can enhance bone matrix and cell attachment. Furthermore, AD and FD microspheres can
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be molded into a variety of shapes and sizes fit for non-load-bearing orthopedic
applications such as craniofacial defect repair.
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CHAPTER 5: FUTURE WORKS AND ALTERNATIVES
The results of the study showed potential bone scaffold characteristics for the
composite chitosan calcium phosphate microsphere based scaffolds. However, there were
issues that need thorough follow-up assessments before the scaffolds can be clinically
applicable. First, the matrix deposition and mineralization were minimally visible under
the scanning electron microscope. A repeat of the mineralization can be conducted to
obtain better measurements of matrix production and mineralization by determining
levels of osteocalcin, hydroxyproline, and calcium. In a previous study with similar AD
scaffolds, cells seeded on the scaffolds had a growth prior to mineralization in a rotary
bioreactor and the scaffolds showed bone matrix deposition occurred at day 14. The
dynamic flow of the medium promoted efficient nutrient and waste exchange and induced
shear stress on the cells as mechanical stimulation. By using the rotary bioreactor in a
follow-up study, sufficient medium diffusion is provided for the entirety of the scaffold.
The second issue to resolve is the slow degradation of the scaffolds. The rate of
scaffold degradation should be equivalent to the rate of bone formation to promote bone
tissue ingrowth and consequently compensate for the loss in mechanical integrity to
prevent scaffold collapse. This can be accomplished by using chitosan with different
DDAs to produce the microspheres, incorporating a higher concentration of calcium
phosphate nanoparticles, and using different solvent acids to dissolve the chitosan.32, 52
To better understand the architectural properties of the scaffolds, a thorough
characterization of scaffold macro- and micro-porosity (focusing on FD microspheres) is
necessary. Pore size, interconnected porosity, surface area, and surface topography are
influential in bone cell proliferation, communication, growth, and attachment,
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respectively. Even though Reves et al. characterized lyophilized composite chitosan
calcium phosphate scaffolds, the drying and scaffold construction techniques were
different which can render different surface physico-chemistry.50 These results can be
utilized to optimize the functional potential of the AD and FD microspheres and its
arrangement to mimic the organization of other bones in the body.
A major concern for bone scaffold functionality is osteoinductivity, the induction
of mesenchymal stem cell (MSC) differentiation into specialized bone cells to regenerate
bone. Osteoinduction can be incorporated into the scaffold by integrating growth factors,
cytokines, and molecular agents that induce MCS differentiation. Bone morphogenic
proteins, vascular endothelial growth factors, and platelet-derived growth factors are
common factors that provoke morphogenesis of bone cells, angiogenesis vascular
endothelial cells, and recruitment of inflammatory and fibroblasts, respectively. The
inherent microporosity of FD microspheres having high absorption potential and protein
affinity of amino acid side chains on chitosan confer advantages for growth factors and
cytokine absorption.
Finally, the issue of scaffold functionality with in vivo models is crucial to obtain
in order for the scaffolds to be used as a clinical alternative to auto- and allo-grafts.
Common models are rat calvarial and rabbit radial critical size defect. Since rat calvarial
and rabbit radial bone are small, scaffold composition is limited to AD or FD
microspheres alone. Furthermore, scaffolds can be also loaded with growth factors to
examine absorption capabilities and elution efficacy within the in vivo model.
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Appendix 1

Apparent Density of AD and FDAD scaffolds

Appendix 2
Degradation study on AD and FDAD scaffolds conducted in December 2009

Compressive Modulus of Degraded Scaffolds
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There is a significant difference between the scaffold types (p=0.005) but no differences
over time.

Degradation by Mass Change
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There is significant difference between the two scaffold types (p<0.001) and over time
(p=0.002).
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Appendix 3

Modulus of AD Scaffolds Hydrated for 4hrs in Water or
PBS Calculated from BlueHill
Modulus (MPa)
Scaffold A - Water

95.48

Scaffold B - Water

76.02

Scaffold A - PBS

87.87

Scaffold B - PBS

97.79

63

Appendix 4
AD vs FDAD mineralization measurement of total protein

Total Protein Normalized to DNA (n=4)

Total Protein (µg/µg DNA)
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Day 21

Day 28

Appendix 5

FD microsphere taken from Keyence VHX-1000 digital microscope.

AD microsphere. Top view.
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Appendix 6
Rotary bioreactor
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Appendix 7
Comparison of culture conditions with all AD scaffolds conducted 2008
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